SCOLR sale
This article was originally published in The Tan Sheet
Executive Summary
The Redmond, Wash-based biopharmaceutical firm divests its probiotics division to focus on development of its drug delivery business, according to a Jan. 5 announcement. A new company created by Steven Moger, SCOLR's former VP-operations & CFO, made the $2.72 mil. purchase, which will include additional amounts contingent on sales and royalties. SCOLR maintains a positive outlook for 2004. "We continue to work aggressively toward initiating new development agreements with other pharmaceutical and OTC potential partners," President & CEO David Wilds maintains...